FLOW FOR LYMPHOMA/ CLPD / LYMPHOMA MRD

Cancer

Report in 192Hrs

At Home

No Fasting Required

Details

Flow cytometry immunophenotyping.

₹22,200₹31,714

30% OFF

Flow for Lymphoma/CLPD/Lymphoma MRD

Why is it done?
- Detects and identifies abnormal lymphocytes using multiparametric flow cytometry to diagnose lymphoid malignancies and chronic lymphoproliferative disorders
- Initial diagnosis of suspected lymphoma, leukemia, and lymphoproliferative disorders presenting with lymphocytosis, lymphadenopathy, or organomegaly
- Monitors minimal residual disease (MRD) during and after treatment to assess treatment response and predict relapse risk
- Immunophenotyping of abnormal cell populations to determine B-cell, T-cell, or myeloid lineage and stage disease
- Performed at initial diagnosis, during treatment monitoring, at end of therapy, and during follow-up surveillance
- Evaluates unusual lymphocytosis or suspected immune abnormalities in both hematologic and non-hematologic malignancies
Normal Range
- Normal Lymphocyte Count: 1.0-4.8 × 10⁹/L or 1,000-4,800 cells/μL
- Normal B-cell percentage: 7-25% of total lymphocytes
- Normal T-cell percentage: 60-85% of total lymphocytes
- Normal NK cell percentage: 5-15% of total lymphocytes
- Normal CD4:CD8 ratio: 1.5-2.5
- Interpretation: Negative/Normal = No abnormal clonal populations detected, normal immunophenotype with proper B and T cell distribution Positive = Presence of monoclonal lymphocyte population with aberrant antigen expression suggesting lymphoid malignancy MRD Negative = No detectable disease below sensitivity threshold (<0.01% to 0.1% depending on methodology) MRD Positive = Detectable abnormal cells present, indicating residual disease
Interpretation
- Monoclonal B-cell population (positive result): Single B-cell clone with restricted surface immunoglobulin (CD19+, CD20+, monotypic). Suggests B-cell lymphoma or chronic lymphocytic leukemia (CLL)
- Monoclonal T-cell population (positive result): Restricted T-cell receptor (TCR) expression suggesting T-cell lymphoma or peripheral T-cell leukemia
- Aberrant antigen expression: Loss of normal antigens (CD5, CD19, CD20) or unexpected coexpression indicates malignancy
- Blastic population: Large cells with high CD34 expression suggests acute leukemia or transformed lymphoma
- MRD positive at end of treatment: Indicates incomplete response, associated with higher relapse risk and poor prognosis
- MRD negative status: Indicates complete remission with undetectable disease, better prognosis and longer disease-free survival
- Increasing MRD levels: Suggests emerging resistance and impending relapse, may warrant therapy modification
- Factors affecting interpretation: Sample quality, timing of collection, specimen type (peripheral blood vs. bone marrow), prior chemotherapy effects, reactive vs. clonal populations
Associated Organs
- Primary organs involved: Blood, bone marrow, lymph nodes, spleen, liver, thymus
- Lymphoid malignancies diagnosed: Chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Hodgkin lymphoma, peripheral T-cell lymphomas, natural killer cell lymphomas
- Associated diseases: Lymphocytic leukemias, myeloproliferative neoplasms with lymphoid involvement, post-transplant lymphoproliferative disorders (PTLD), viral-associated lymphoproliferations
- Potential complications of malignancy: Leukostasis (high white blood cell counts), tumor lysis syndrome, infectious complications from immunosuppression, organ infiltration, secondary malignancies, treatment-related toxicity
- Associated systemic manifestations: B-symptoms (fever, night sweats, weight loss), lymphadenopathy, hepatosplenomegaly, cytopenias, autoimmune phenomena
Follow-up Tests
- If positive result: Cytochemistry and morphology, immunohistochemistry on tissue biopsy, cytogenetics/FISH for prognostic markers (t(9;22), t(14;18), del(17p), del(11q), TP53 mutations), molecular studies (clonality assessment, BCR-ABL PCR, IGH rearrangement)
- Imaging studies for staging: CT chest/abdomen/pelvis, PET-CT for staging and response assessment
- Treatment monitoring (during therapy): Repeat flow cytometry every 2-4 cycles of chemotherapy, more frequent for aggressive lymphomas or acute leukemias
- End of treatment assessment: MRD flow cytometry to assess complete remission status, provides prognostic information for relapse risk
- Surveillance/follow-up monitoring: Every 3-6 months for first 2 years, then annually. MRD-positive patients require more frequent monitoring
- Complementary investigations: Complete blood count with differential, lactate dehydrogenase (LDH), bone marrow aspiration/biopsy for disease burden assessment, gene sequencing panels for mutation analysis
- Special testing for specific diagnoses: HCV antibody and RNA for lymphomas associated with hepatitis C, EBV serology for EBV-associated diseases, HIV testing
Fasting Required?
- Fasting Required: No
- Dietary restrictions: None required
- Medication considerations: Continue all routine medications including chemotherapy agents if being monitored during treatment. Inform laboratory of recent chemotherapy or biologic therapy
- Specimen collection: Peripheral blood (EDTA tube - lavender top) or bone marrow aspirate. Sample should be processed within 24 hours for optimal results
- Timing recommendations: Optimal timing before 11 AM for same-day processing. For serial MRD monitoring, collect samples at consistent time of day and cycle point to ensure comparability
- General preparation: Patient should be in calm state before venipuncture. Avoid excessive exercise or stress before testing. Inform phlebotomist of any bleeding disorders or anticoagulation therapy
- Special considerations: Delayed processing or improper storage can affect cell viability and phenotype. For MRD studies, exact specimen timing relative to therapy cycles is critical for accurate interpretation

How our test process works!